Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXAMETHASONE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Adrenal insufficiency,Inflammatory conditions,Allergic disorders,Autoimmune diseases,Cerebral edema,COVID-19 treatment (off-label),Multiple myeloma (combination therapy),Nausea/vomiting (chemotherapy-induced)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via CYP3A4; also metabolized by 11β-HSD2 in peripheral tissues.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 77% bound to albumin; minor binding to corticosteroid-binding globulin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vd ~0.8-1.0 L/kg; indicates extensive tissue distribution (crosses placenta, enters milk, penetrates CNS).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 80-90%; IM: 80-100%; topical: negligible (systemic absorption <1% with intact skin).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for GFR <30 m L/min or dialysis; monitor for fluid retention.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with caution, reduce dose by 75%.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
0.08-0.3 mg/kg/day oral/IV/IM in 2-4 divided doses; asthma exacerbation: 0.6 mg/kg IV/IM (max 16 mg) once; croup: 0.6 mg/kg oral/IM once.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, and adrenal suppression; consider increased risk of fractures and infections.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None required per FDA labeling.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Immunosuppression/increased infection risk,Adrenal suppression with prolonged use,Osteoporosis with long-term therapy,Hyperglycemia/diabetes exacerbation,Gastrointestinal perforation risk,Myopathy,Ocular effects (glaucoma, cataracts),Psychiatric disturbances
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Systemic fungal infections,Hypersensitivity to dexamethasone or components,Administration of live vaccines (relative contraindication),Idiopathic thrombocytopenic purpura (IM use in children)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Limit high-sodium foods (processed snacks, canned soups) to reduce fluid retention. Avoid grapefruit and grapefruit juice as they increase dexamethasone levels via CYP3A4 inhibition. Increase potassium intake (bananas, spinach) if on loop diuretics.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppression, growth restriction, and altered brain development. Chronic use increases risk of preterm birth and low birth weight.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Dexamethasone is excreted into breast milk in low concentrations (M/P ratio approximately 0.5). Doses ≤15 mg/day are generally considered compatible with breastfeeding; higher doses require monitoring for infant adrenal suppression. Avoid breastfeeding within 4 hours of oral dose.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No routine dose adjustment required; however, increased clearance in pregnancy may necessitate higher doses for desired effect (e.g., fetal lung maturation). Consider lower doses for chronic conditions due to increased sensitivity. Taper gradually to avoid adrenal crisis.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Intravenous dexamethasone causes perineal itching due to phosphate esters; warn patients. Taper after prolonged use (>3 weeks) to avoid adrenal crisis. Single dose of 10 mg may elevate INR in warfarin patients via CYP3A4 inhibition. Monitor blood glucose and potassium during therapy.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take with food or milk to reduce stomach upset.,Do not stop suddenly; follow taper schedule.,Report signs of infection (fever, sore throat) as steroid masks symptoms.,Avoid live vaccines during therapy.,Carry a steroid alert card if on long-term therapy.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Dexamethasone, a potent corticosteroid, induces various cytochrome P450 (CYP) enzymes, including CYP2D6, which is primarily responsible for the metabolism of atomoxetine. Concurrent use can decrease atomoxetine metabolism, leading to elevated plasma concentrations and increased risk of atomoxetine-related adverse effects such as insomnia, dry mouth, nausea, and cardiovascular effects like hypertension and tachycardia. Close monitoring for atomoxetine toxicity is warranted when dexamethasone is coadministered."
"Dexamethasone, a potent corticosteroid, induces cytochrome P450 (CYP) 3A4 enzymes, which metabolize Vincristine, a vinca alkaloid chemotherapeutic agent. This induction increases Vincristine clearance, reducing its systemic exposure and potentially compromising its antineoplastic efficacy. Clinically, this may lead to suboptimal tumor response or require dose adjustments."
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXAMETHASONE vs ACTIQ, answered by our medical review team.
DEXAMETHASONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXAMETHASONE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXAMETHASONE is: 0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXAMETHASONE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXAMETHASONE is classified as Category D/X. First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppress. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.